Investor Presentaiton

Sun Pharma today Note: US Formulations 5th largest generics company in US* with a strong pipeline (139 ANDAS & 3 NDAs awaiting approval) Presence in generics, Specialty and branded segments with more than 422 approved products FY18 sales: US$ 1,357 mn (2) India 32% FY18 International 68% Emerging Markets Geographical sales split Market cap: US$ 17 bn (1) India Branded Generics No.1 ranked with 13 classes of doctor categories Leading position in high growth chronic therapies Specializes in technically complex products FY18 sales: US$ 1,246 mn (2) Gross Sales: US$ 4,044 mn (2) EBITDA: US$ 804 (21% margin) (2) R&D Investment: 8.6% of Sales Globalized supply chain 54% owned by promoter group Strong balance sheet, low debt Strong product pipeline Presence in over 100 countries across Africa, Americas, Asia and Eastern & Central Europe Key focus markets - Brazil, Mexico, Russia, Romania, South Africa, and complementary & affiliated markets FY18 sales: US$ 751 mn (2) (1) As of May, 31, 2018 using spot exchange rate of INR/USD = 67.62 (2) Using average exchange rate for FY17 of INR/USD = 64.46 # Includes Western Europe, Canada, Australia & New Zealand, Japan and other markets. All sales numbers in US$ for 12 months ended March 31, 2018. * Source: Evaluate Pharma Estimates for 12 months ended Dec 2017 © Sun Pharmaceutical Industries Limited. All Rights Reserved. Revenue Break-up SUN PHARMA Emerging Markets 19% Western Europe & Other Markets # 11% India Branded Generics 31% FY18 API & Others 6% US Formulation 33% Western Europe, Canada, Japan ANZ & others Presence across majority of markets in Western Europe, Canada, Japan and A&NZ Product portfolio includes differentiated offerings for hospitals, injectables and generics for retail market FY18 sales: US$ 461 mn (2) 6

View entire presentation